Any feedback?
Please rate this page
(search_result.php)
(0/150)

BRENDA support

Refine search

Search Application

show results
Don't show organism specific information (fast!)
Search organism in taxonomic tree (slow, choose "exact" as search mode, e.g. "mammalia" for rat,human,monkey,...)
(Not possible to combine with the first option)
Refine your search

Search term:

Results 1 - 10 of 31 > >>
EC Number Application Commentary Reference
Display the word mapDisplay the reaction diagram Show all sequences 3.4.24.83diagnostics the anthrax lethal toxin neutralization assay (TNA) measures the ability of antibodies to neutralize the cytotoxicity of anthrax lethal toxin rather than quantifying total antibody through a conjugated species-specific secondary antibody. TNA may provide a more relevant immunological measure, as it quantitates functional antibodies only rather than total protective antigen-binding antibodies. In this study, TNA data are generated in several different laboratories to measure the immune responses in rabbits, nonhuman primates, and humans. A collaborative study is conducted in which 108 samples from the three species are analyzed in seven independent laboratories. This study demonstrates that the TNA is a panspecies assay that can be performed in several different laboratories with a high degree of quantitative agreement and precision 697440
Display the word mapDisplay the reaction diagram Show all sequences 3.4.24.83diagnostics the development, performance characteristics and validation using human serum of a robust and rugged format of the LTx neutralization activity (TNA) assay is reported and its application in evaluating immune serum from humans, Rhesus macaques and rabbits. This format uses standardized and characterized reagents in conjunction with customized interpretive software and a novel mathematical algorithm to calculate and extrapolate multiple reportable values, in addition to ED50, with high specificity, analytical sensitivity, accuracy and precision. This LTx neutralization activity (TNA) assay format is proposed as a unifying platform technology 696000
Display the word mapDisplay the reaction diagram Show all sequences 3.4.24.83medicine administration of lethal factor proteases early in the infection inhibits dissemination of vegetative bacteria to the organs in the first 32 h following infection. Neutralizing antibodies against edema factor also inhibit bacterial dissemination with similar efficacy 733112
Display the word mapDisplay the reaction diagram Show all sequences 3.4.24.83medicine anthrax lethal factor is a specific biomarker of active infection by Bacillus anthracis 718573
Display the word mapDisplay the reaction diagram Show all sequences 3.4.24.83medicine anthrax toxin entry and activity differs among immune cells. Macrophages, dendritic cells, and B cells display higher activity of a of fusion protein of the anthrax toxin lethal factor N-terminal domain LFn, residues 1-254, with beta-lactamase, i.e. LFnBLA, than CD4+ and CD8+ T cells in both spleen cell suspension and the purified samples of individual cell types. Expression of anthrax toxin receptor CMG2 is higher in CD4+ and CD8+ T cells, which is not correlated to the intracellular LFnBLA activity 713352
Display the word mapDisplay the reaction diagram Show all sequences 3.4.24.83medicine blood borne lethal toxin is a novel therapeutic target for combating anthrax 720419
Display the word mapDisplay the reaction diagram Show all sequences 3.4.24.83medicine engineered lethal anthrax toxin prevents tumor growth by inhibiting angiogenesis (10 nmol/l engineered protective antigen + 5.5 nmol/l lethal factor) 700136
Display the word mapDisplay the reaction diagram Show all sequences 3.4.24.83medicine human medical countermeasures for anthrax 669066
Display the word mapDisplay the reaction diagram Show all sequences 3.4.24.83medicine in a murine model of intoxication, lethal factor causes the dose-dependent disruption of intestinal epithelial integrity, characterized by mucosal erosion, ulceration, and bleeding. The pathology correlates with a blockade of intestinal crypt cell proliferation, accompanied by marked apoptosis in the villus tips. Treated mice nearly uniformly develop systemic infections with commensal enteric organisms within 72 hours of administration. Intestinal pathology depends upon lethal factor proteolytic activity and is partially attenuated by co-administration of broad spectrum antibiotics 735046
Display the word mapDisplay the reaction diagram Show all sequences 3.4.24.83medicine inducing strong mucosal and systemic immune responses against both anthrax toxins and bacilli after nasal immunization using a synthetic double-stranded RNA (dsRNA), polyriboinosinic-polyribocytidylic acid as adjuvant. The capsular poly-gamma-D-glutamic acid (PGA) from bacillus is immunogenic when conjugated to a carrier protein and dosed intranasally to mice. The nasal immunization with the poly-gamma-D-glutamic acid-carrier protein conjugate in combination with the anthrax protective antigen (PA) protein induces both anti-PGA and anti-PA immune responses in mouse sera and lung mucosal secretions. The anti-PA antibody response is shown to have anthrax lethal toxin neutralization activity. The anti-PGA Abs induced are able to activate complement and kill PGA-producing bacteria. It is feasible to develop a novel dual-action nasal anthrax vaccine 670987
Results 1 - 10 of 31 > >>